The clinically optimized microarray technology forms the basis of next generation laboratory-based diagnostics. The microarray technology targets the new and rapidly growing market for personalized medicine, using information about a person’s genetic make-up to tailor strategies for the detection, treatment or prevention of disease.
Microarray technology resides on a one-square-centimeter silicon chip that contains up to a thousand DNA probes that identify specific human gene sequences of diagnostic interest. With this leading-edge technology, QuantRx is in the forefront of the laboratory-based testing market with new technology to allow microarrays to be used as a cost-effective diagnostic or population scale screening test.
Through its affiliate company Genomics USA (GUSA), QuantRx has as its focus population-scale typing of HLA – the human leukocyte antigen, a segment of the genome that is essentially the core of the human immune response. HLA is composed of proteins that play a critical role in activating the body’s immune system to respond to foreign organisms. Typing HLA results in the ability to detect a majority of disorders related to the immune system.
The ability of an individual to respond to a particular vaccine is also determined by his or her HLA type. An initial application for this HLA-based technology is in vaccine development and personalized vaccine delivery.